Fleury S.A. (BOVESPA:FLRY3) is looking for inorganic growth. Jeane Tsutsui, Chief Executive Officer said,"EBITDA totaled BRL 506 million this quarter with a 27.1% margin. These figures demonstrate the consistency of our results and give us a peace of mind to continue with our strategy of organic and inorganic growth and to leverage this business combination with Pardini, to improve the services offer to patients, doctor, partner laboratories and HMOs".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.61 BRL | +4.28% | +4.06% | -19.01% |
Mar. 08 | Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024 | |
Mar. 07 | Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.01% | 1.55B | |
-17.89% | 8.25B | |
+39.20% | 3.57B | |
-39.11% | 2.46B | |
-8.06% | 2.46B | |
-7.35% | 2.38B | |
-12.61% | 1.81B | |
-40.66% | 1.21B | |
+7.56% | 1.11B | |
-15.34% | 1.03B |
- Stock Market
- Equities
- FLRY3 Stock
- News Fleury S.A.
- Fleury S.A Seeks Inorganic Growth